

Figure 2. Endomyocardial biopsy (EMB) complications over time since heart transplantation (HTx). A. Scatterplot of endomyocardial biopsies for all 326 HTx patients. Each gray dot represents an EMB sample negative for EMB complications and each red diamond represents an EMB sample associated with a complication. EMB complications show a pattern of occurring within the first month after HTx. B. Barplot showing percentage of EMB complications within each time interval. There is a significant difference in percentage of EMB complications occurring in the first month compared to the rest of the first year after HTx (p < 0.001).




Figure 3. Treated acute rejection (AR) over time since heart transplantation (HTx). A. Scatterplot of endomyocardial biopsies for all 326 HTx patients. Each gray dot represents an EMB sample negative for treated AR and each red diamond represents an EMB sample positive for treated AR does not show a pattern of occurring at a higher rate early after HTx (i.e., within the first 6 months) in the contemporary era. **B**. Barplot showing percentage of treated AR within each time interval. There is no significant difference in the percentage of treated AR in 0-6 months compared to 6-12 months after HTx (p = 0.17).






Figure 4. Endomyocardial biopsy complication (EMB) and treated acute rejection (AR) over time since heart transplantation (HTx). A. Surveillance EMB incidence curves for benefit and risk. EMB complications incidence acutely increases within the first month after HTx. Incidence of treated AR does not increase above the rate of EMB complications for surveillance EMBs. B. For cause EMB incidence curves for benefit and risk. The incidence of treated AR increases above the rate of EMB complications in for cause EMBs within the first month after HTx.




Table 1. Characteristics of Subjects and Endomyocardial Biopsies. DCD, donation after cardiac death; DPP-NMP, direct procurement perfusion-normothermic machine perfusion; ICM, ischemic cardiomyopathy; NICM, nonischemic cardiomyopathy; NRP-CSS, normothermic regional perfusion-cold static storage; PHM, predicted heart mass; PRA, panel reactive antibodies; VAD, ventricular assist device

	Ν					
Donor characteristics						
Age, y, mean (SD)	321	33.3 (10.7)				
Male, N (%)	326	267 (81.9)				
Recipient characteristics						
Age, y, mean (SD)	326	55.5 (13.8)				
Male, N (%)	326	257 (78.8)				
Race						
Asian, N (%)	326	24 (7.4)				
Black, N (%)	326	44 (13.5)				
Native American, N (%)	326	2 (0.6)				
Other Race, N (%)	326	27 (8.3)				
Pacific Islander, N (%)	326	4 (1.2)				
White, N (%)	326	225 (69.0)				
Ethnicity						
Hispanic or Latino, N (%)	326	98 (30.1)				
Not Hispanic or Latino, N (%)	326	228 (69.9)				
Transplant characteristics						
Multi-organ transplant, N (%)	326	53 (16.3)				
Total donor ischemic time, min, mean (SD)	319	211 (70)				
Sex mismatch, N (%)	326	54 (16.6)				
PHM difference, % recipient PHM, mean (SD)	321	5.9 (21.7)				
Sensitized patients (PRA \geq 10%)	319	58 (18.2)				
VAD use, N (%)	326	108 (33.1)				
Indication for Transplant	•					
NICM, N (%)	326	188 (57.7)				
ICM, N (%)	326	113 (34.7)				

Congenital, N (%)	326	18 (5.5)			
Retransplant, N (%)	326	7 (2.1)			
Induction therapy					
Thymoglobulin, N (%)	326	109 (33.4)			
Basiliximab, N (%)	326	26 (8.0)			
Eculizumab, N (%)	326	2 (0.6)			
DCD, N (%)	326	65 (19.9)			
NRP-CSS	326	49 (15.0)			
DPP-NMP	326	16 (4.9)			
Endomyocardial biopsy characteristics					
Time post-transplant, d, median (IQR)	2769	100 (48-217)			
Concurrent DSA, N (%)	2757	233 (8.5)			
Concurrent cardiac allograft dysfunction, N (%)	2769	135 (4.9)			

Table 2. Endom	vocardial biopsv	complications.
I doit I Bindom	, ocal anal blops,	complications

	Endomyocardial cases	Unique heart transplant patients
Clinically significant pericardial effusion – no. of patients/total no. (%)	33/45 (73.3)	31/41 (75.6)
Pericardiocentesis with pericardial drain – no. of patients/total no.	25/33	24/31
Surgical pericardial window – no. of patients/total no.	1/33	1/31
Tricuspid valve injury – no. of patients/total no. (%)	3/45 (6.7)	3/41 (7.3)
Inadvertent arterial access – no. of patients/total no. (%)	3/45 (6.7)	3/41 (7.3)
Failed venous access attempt – no. of patients/total no. (%)	4/45 (8.9)	4/41 (9.8)
Right atrial lead dislodgement – no. of patients/total no. (%)	1/45 (2.2)	1/41 (2.4)
Extraction of embedded bioptome – no. of patients/total no. (%)	1/45 (2.2)	1/41 (2.4)

Table 3. Multi-predictor logistic regression for treated acute rejection for all endomyocardial biopsies. CI, confidence interval; DSA, donor specific antibody; HTx, heart transplant; OR, odds ratio.

Variables	OR	95% CI	p-value
For cause indication	9.17	[4.56-18.46]	$p_{c} < 0.001$
Concurrent DSA	5.12	[2.56-10.25]	p _c < 0.001
Inpatient status	1.74	[0.93-3.26]	$p_{c} = 0.124$
Right atrial pressure (per 1 mmHg)	1.06	[1.00-1.13]	$p_{c} = 0.124$
Fick cardiac index (per 1 LPM/m2)	0.65	[0.44-0.96]	p _c = 0.093
Time since HTx (per week)	1.00	[1.00-1.00]	$p_{c} = 0.909$

SECTION 1: SUPPLEMENTARY METHODS

1.1 Study Design: All EMBs at UC San Diego Health are guided by fluoroscopy and at least 3 separate passes for EMB samples are attempted as recommended by the ISHLT.¹ Estimated glomerular filtration rate (GFR) was calculated using the chronic kidney disease epidemiology collaboration equation, which does not include a race factor.² Patients on hemodialysis were given an estimated GFR of 15 mL/min per 1.73 m².

1.2 EMB complications: Potential EMB complications included: new pericardial effusions that required intervention (i.e., pericardiocentesis or surgical pericardial window), new pericardial effusions moderate or greater in size that was increased by more than 1 grade, tricuspid valve injury, inadvertent arterial access, failed venous access attempts, atrial or ventricular arrhythmias, atrioventricular block, pneumothorax, hemothorax, access site infection or hematoma, arteriovenous fistula, pseudoaneurysm, vasovagal reaction, and coronary artery fistula. Any other unexpected incidents were also marked as potential complications. To meet criteria for a procedure-related pericardial effusion, there had to be prior cardiac imaging by echocardiography or computed tomography for comparison to demonstrate that the pericardial effusion was a new finding after the procedure. To meet criteria for a procedure-related tricuspid valve injury, there had to be a prior echocardiogram for comparison with a new diagnosis of moderate or greater tricuspid valve regurgitation that was increased by more than 1 grade and was found to be persistent in subsequent echocardiograms.³ Routine echocardiograms are performed at 2 weeks, 1 month, 3 months, and annually post-HTx for routine monitoring of cardiac allograft function at UC San Diego Health. Additional echocardiograms were performed as clinically indicated at the request of the clinical team.

1.3 For Cause vs Surveillance: At UC San Diego Health, surveillance EMB are performed biweekly for the first 3 months and monthly afterwards. After 1 year post-HTx, surveillance EMBs are no longer performed except in rare cases where a patient is deemed high risk for recurrent AR. Instead, gene expression profile (GEP) testing is performed for AR surveillance every 3 months until 3 years post-HTx. In June 2021, we revised our clinical protocol to begin donor-derived cell-free DNA (dd-cfDNA) and GEP testing at 6 months after HTx in place of surveillance EMBs for low risk patients (**Appendix**).

1.4 Biopsy-defined Rejection: At UC San Diego Health, a weekly pathologic review of all EMB samples is performed as previously described.⁴

1.5 Blood-based biomarkers: At UC San Diego Health, we began using donor-derived cell-free DNA (dd-cfDNA; AlloSure®; CareDx; Brisbane, California) for clinical use in August 2019 in addition to gene-expression profiling (GEP; AlloMap®; CareDx; Brisbane, California) for AR surveillance monitoring. Our initial protocol was to obtain dd-cfDNA testing with surveillance

EMBs to establish an appropriate threshold for performing EMBs at UC San Diego Health. In June 2021, we revised our clinical protocol to include dd-cfDNA with GEP testing at 6 months after HTx in place of surveillance EMBs for low risk patients. Surveillance EMBs were continued until 1 year post-HTx in high risk patients. Immune cell function (Immuknow®; Viracor-Eurofins; Lee's Summit, Missouri) was also routinely obtained monthly in the first year post-HTx, every 3 months for year 2 post-HTx, every 4 months for year 3 post-HTx, every 6 months for years 4 and 5 post-HTx, and annually thereafter.

1.6 Statistical Analyses: Lme4 package was used for mixed effects logistic regression and Poisson models.⁵ Cross-validation was performed using the boot package.⁶ Figures were produced using the package ggplot2.⁷ Kaplan-Meier curves were produced using the package survival.⁸

SECTION 2: SUPPLEMENTARY RESULTS

Table S1. Additional characteristics of subjects and endomyocardial biopsies. ACR, acute cellular rejection; AMR, antibody mediated rejection; BUN, blood urea nitrogen; DOAC, direct oral anticoagulant; DPP-NMP, direct procurement perfusion-normothermic machine perfusion; ECMO, extracorporeal membrane oxygenation; HTX, heart transplant; IABP, intra-aortic balloon pump; LPM, liters per minute; MCS, mechanical circulatory support; NRP-CSS, normothermic regional perfusion-cold static storage; UNOS, United Network of Organ Sharing

Variables	Ν	Value				
Recipient characteristics						
Recipient body mass index, kg/m ² , mean (SD)	326	26.3 (4.5)				
Donor characteristics						
Donor body mass index, kg/m ² , mean (SD)	309	27.2 (5.9)				
Transplant characteristics						
Primary graft dysfunction	326	61 (18.7)				
UNOS status						
Status 1 (post 10/2018), N (%)	316	10 (3.2)				
Status 2 (post 10/2018), N (%)	316	99 (31.3)				
Status 3 (post 10/2018), N (%)	316	45 (14.2)				
Status 4 (post 10/2018), N (%)	316	81 (25.6)				
Status 5 (post 10/2018), N (%)	316	13 (4.1)				
Status 6 (post 10/2018), N (%)	316	33 (10.4)				
Status 1A (pre 10/2018), N (%)	316	23 (7.3)				
Status 1B (pre 10/2018), N (%)	316	10 (3.2)				
Status 2 (pre 10/2018), N (%)	316	2 (0.6)				
Temporary MCS pre-transplant						
ECMO, N (%)	321	8 (2.5)				
IABP, N (%)	321	91 (28.4)				
Temporary MCS post-transplant						
ECMO, N (%)	321	16 (5.0)				
IABP, N (%)	321	51 (15.9)				
NRP-CSS						
Total ischemic time, min, median (IQR)	49	236.0 (204.0-273.0)				
Functional warm ischemic time, min, median (IQR)	49	24.0 (20.0-37.0)				

Cold ischemic time, min, median (IQR)	49	178.0 (147.0-230.0)
Warm ischemic time, min, median (IQR)	49	48.0 (43.0-51.0)
DPP-NMP		
Total ischemic time, min, median (IQR)	16	98.0 (87.5-109.5)
Functional warm ischemic time, min, median (IQR)	16	24.5 (18.0-29.2)
Cold ischemic time, min, median (IQR)	16	44.0 (41.0-51.5)
Warm ischemic time, min, median (IQR)	16	48.5 (44.8-53.2)
Endomyocardial biopsy characteristics	_	
For cause indication	2769	499 (18.0)
Cardiac allograft vasculopathy, N (%)	224	14 (6.3)
Dialysis, N (%)	2769	36 (1.3)
History of ACR, N (%)	2769	334 (1.2)
History of AMR, N (%)	2769	360 (13.0)
Pericardial effusion, N (%)	2769	49 (1.8)
Trainee involved, N (%)	2769	855 (30.9)
Outpatient status, N (%)	2769	2182 (78.8)
Fluoroscopy time, min, mean (SD)	2624	3.3 (3.3)
Combined with left heart catheterization	2769	5 (0.2)
Number of biopsy samples, median (IQR)	2762	4.0 (4.0-5.0)
Venous access site		
Femoral, N (%)	2762	103 (3.7)
Right internal jugular, N (%)	2762	2333 (84.5)
Left internal jugular, N (%)	2762	288 (10.4)
Right brachial, N (%)	2762	38 (1.4)
Bioptome size		
7 French, N (%)	2759	1506 (54.6)
6 French, N (%)	2759	1017 (36.9)
5.5 French, N (%)	2759	236 (8.6)
Anticoagulant use, N (%)	2769	345 (12.5)
DOAC, N (%)	345	327 (94.8)
Warfarin, N (%)	345	17 (4.9)

Heparin infusion, N (%)	345	1 (0.3)						
Right heart catheterization	Right heart catheterization							
Right atrial pressure, mmHg, mean (SD)	1827	6.3 (4.1)						
Pulmonary arterial pressure, mmHg, mean (SD)	1825	20.4 (6.0)						
Pulmonary capillary wedge pressure, mmHg, mean (SD)	1805	11.7 (5.1)						
Fick cardiac index, LPM/m ² , mean (SD)	1824	3.2 (0.8)						
Laboratory values								
BUN, mg/dL, mean (SD)	2733	31.1 (17.9)						
Creatinine, mg/dL, mean (SD)	2732	1.4 (0.6)						
Hemoglobin, g/dL, mean (SD)	2769	11.3 (2.0)						
Platelets, 1000/mm ³ , mean (SD)	2769	248 (90.5)						

Table S2. Single predictor logistic regression for endomyocardial biopsy complications. ACR, acute cellular rejection; AMR, antibody mediated rejection; BMI, body mass index; BUN, blood urea nitrogen; CI, confidence interval; DPP-NMP, direct procurement perfusion-normothermic machine perfusion; DSA, donor specific antibody; ECMO, extracorporeal membrane oxygenation; eGFR, estimated glomerular filtration rate; EMB, endomyocardial biopsy; HTx, heart transplant; IABP, intra-aortic balloon; NRP-CSS, normothermic regional perfusion-cold static storage; OR, odds ratio; PHM, predicted heart mass; UNOS, United Network Organ Sharing.

Variables	No. of EMBs	Total EMB complications	No. of patients with EMB complications	OR	95% CI	p-value
Recipient characteristics						
Age (per 1-y increment)	2769	45	41	1.01	[0.99-1.03]	p = 0.390
Male sex	2769	45	41	1.63	[0.72-3.73]	p = 0.243
Race and ethnicity	2769	45	41	_	_	p = 0.168
Recipient BMI (per kg/m ²)	2769	45	41	1.01	[0.94-1.08]	p = 0.813
Multi-organ transplant	2769	45	41	1.25	[0.58, 2.66]	p = 0.571
HTx indication	2769	45	41	_	-	P = 0.250
Donor characteristics	•					
Age (per 1-y increment)	2752	45	41	0.99	[0.96-1.02]	p = 0.468
Male sex	2769	45	41	0.84	[0.39-1.80]	p = 0.655
Donor BMI (per kg/m ²)	2752	45	41	0.96	[0.91-1.02]	p = 0.178
Transplant characteristics			-			
UNOS status	2734	45	41	_	_	p = 0.389
Induction therapy	2769	45	41	_	-	p = 0.377
Total donor ischemic time	2735	45	41	1.00	[1.00-1.00]	p = 0.967
PHM difference	2752	45	41	0.99	[0.97-1.01]	p = 0.208
Primary graft dysfunction	2769	45	41	1.63	[0.83-3.18]	p = 0.154
Donation after cardiac death	2769	45	41	0.75	[0.34-1.64]	p = 0.471
DPP-NMP	2769	45	41	0.34	[0.05-2.55]	p = 0.294
NRP-CSS	2769	45	41	0.90	[0.39-2.08]	p = 0.812
ECMO pre-HTx	2748	45	41	0.70	[0.09-5.33]	p = 0.727
ECMO post-HTx	2748	45	41	2.11	[0.71-6.28]	p = 0.178
IABP pre-HTx	2748	45	41	1.88	[1.02-3.44]	p = 0.042
IABP post-HTx	2748	45	41	1.15	[0.54-2.45]	p = 0.720

Within 1 month of HTx	2769	45	41	13.05	[6.82-24.97]	p < 0.001
Time since HTx (per week)	2769	45	41	0.92	[0.89-0.96]	p < 0.001
Surveillance indication	2769	45	41	1.78	[0.69-4.56]	p = 0.229
Bioptome size	2759	39	36	-	_	p = 0.371
Venous access site	2762	42	38	-	-	p = 0.177
Fluoroscopy time (per min)	2624	39	37	1.05	[0.99-1.11]	p = 0.104
Concurrent graft dysfunction	2769	45	41	0.91	[0.21-3.87]	p = 0.899
Concurrent DSA	2758	45	41	0.49	[0.12-2.08]	p = 0.336
De novo DSA	2757	45	41	1.72	[0.40-7.31]	p = 0.460
Number of EMB samples	2762	39	36	1.01	[0.74-1.39]	p = 0.935
Anticoagulant use	2769	45	41	1.08	[0.45-2.60]	p = 0.865
Hemodialysis	2769	45	41	3.48	[0.75-16.07]	p = 0.110
Trainee involvement	2769	45	41	1.83	[1.00-3.33]	p = 0.048
ACR	2752	38	35	_	_	p = 0.614
AMR	2754	38	35	-	_	p = 0.484
Inpatient status	2769	45	41	4.04	[2.22-7.34]	p < 0.001
Combined with left heart catheterization	2769	45	41	-	-	p = 1.0
Right heart catheterization						
Right atrial pressure (per 1 mmHg)	1827	37	35	1.11	[1.04-1.19]	p = 0.001
Pulmonary artery pressure (per 1 mmHg)	1825	37	35	1.05	[1.00-1.10]	p = 0.066
Pulmonary capillary wedge pressure (per 1 mmHg)	1805	35	34	1.09	[1.03-1.16]	p = 0.002
Fick cardiac index (per 1 LPM/m ²)	1824	37	35	1.10	[0.74-1.64]	p = 0.639
Laboratories						
BUN (per 1 mg/dL)	2733	43	39	1.02	[1.01-1.03]	p < 0.001
Creatinine (per 1 mg/dL)	2732	43	39	1.19	[0.80-1.78]	p = 0.393
eGFR (per 1 mL/1.73 m ²)	2769	45	41	0.98	[0.96-1.01]	p = 0.158
Hemoglobin (per 1 g/dL)	2769	45	41	0.70	[0.59-0.83]	p < 0.001
Platelets (per 1000/mm ³)	2769	45	41	1.00	[1.00-1.00]	p = 0.798

White blood cells (per 1000/mm ³)	2769	45	41	1.16	[1.09-1.23]	p < 0.001
---	------	----	----	------	-------------	-----------

Rejection subtype	All rejection	Treated rejection
Acute cellular rejection (ACR)		
0R, samples/total (%)	1549/2752 (56.3)	0/1549 (0)
1R, samples/total (%)	1070/2752 (38.9)	0/1070 (0)
2R, samples/total (%)	40/2752 (1.5)	40/40 (100)
3R, samples/total (%)	4/2752 (0.1)	4/4 (100)
Antibody mediated rejection (AMR)		
pAMR0, samples/total (%)	2619/2754 (95.1)	1/2619 (0.04)
pAMR1, samples/total (%)	47/2754 (1.7)	19/47 (40.4)
pAMR2, samples/total (%)	35/2754 (1.3)	28/35 (80.0)
pAMR3, samples/total (%)	0/2754	_
Mixed rejection		
ACR - 2R/pAMR1, samples/total (%)	4/2752 (0.1)	4/4 (100)
ACR - 2R/pAMR2, samples/total (%)	3/2752 (0.1)	3/3 (100)

Table S3. Breakdown of all endomyocardial biopsy samples by rejection subtype.


Rejection subtype	Surveillance	Treated surveillance	For cause	Treated for cause
Acute cellular rejection				
0R, samples/total (%)	217/372 (58.3)	-	25/41 (61.0)	_
1R, samples/total (%)	151/372 (40.6)	-	14/41 (34.1)	_
2R, samples/total (%)	3/372 (0.8)	3/3 (100)	2/41 (4.9)	2/2 (100)
3R, samples/total (%)	1/372 (0.3)	1/1 (100)	0/41	_
Antibody mediated rejection				
pAMR0, samples/total (%)	368/375 (98.1)	-	39/48 (81.3)	_
pAMR1, samples/total (%)	7/375 (1.9)	1/7 (14.3)	7/48 (14.6)	6/7 (85.7)
pAMR2, samples/total (%)	0/375	-	2/48 (4.2)	2/2 (100)
pAMR3, samples/total (%)	0/375	-	0/48	_
Mixed rejection	0/375	_	0/48	_

Table S4. Breakdown of endomyocardial biopsy samples performed within 1 month of heart transplant.

Infection	
COVID-19 pneumonia, N (%)	2 (8.3)
Bacterial, N (%)	8 (33.3)
Fungal, N (%)	1 (4.2)
Acute rejection	
Acute cellular rejection, N (%)	0
Antibody mediated rejection, N (%)	3 (12.5)
Cardiac allograft vasculopathy, N (%)	2 (8.3)
Cancer, N (%)	3 (12.5)
Other, N (%)	5 (20.8)
Total	24

Table S5. Causes of death in study patients.

Central Illustration:



dd-cfDNA, donor-derived cell-free DNA; DSA, donor specific antibody; EMB, endomyocardial biopsy; HTx, heart transplant; LVEF, left ventricular ejection fraction

Appendix.

Moderate-High Risk for Rejection (heart transplant):

- 1. Giant Cell Myocarditis
- 2. Protein-losing Enteropathy with Hypogammaglobulinemia or on Immunoglobulin Treatment
- 3. Panel of Reactive Antibodies > 40%
- 4. Prior Desensitization
- 5. Positive Prospective or Retrospective Crossmatch at Time of Transplant

Low Risk for Rejection (heart transplant):

No criteria for moderate-high risk for rejection.

Dual-organ Transplant:

Heart-Kidney: Follows heart only protocol.

Heart-Lung: Case by case biopsy schedule.

Heart-Liver: Follows low risk for rejection heart only protocol.

Post-transplant Month 1-3 Schedule

Right Heart Catheterization and Endomyocardial Biopsy Week 2, 4, 6, 8, 10, 12

Post-transplant Month 4-6

Endomyocardial Biopsy Week 16, 20, 24

Post-transplant Month 7-11

Low-risk for rejection:

No scheduled biopsies. If there is a de novo donor specific antibody or an episode of treated rejection seen in the first 6 months, these patients should be moved to the moderate-high risk for rejection category.

Moderate-high risk for rejection: Endomyocardial Biopsy Week 28, 32, 36, 40, 44

Post-transplant Indication for Biopsy Outside of Prespecified Testing Time Frame

Symptoms or signs of rejection Graft dysfunction (left ventricular ejection fraction < 50%) AlloSure $\mathbb{R} \ge 0.19\%$ or 2x established baseline on serial checks Arrhythmias (if new type of arrhythmias is seen, consider repeat biopsy)

SECTION 3: REFERENCES

- Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, Andersen CB, Angelini A, Berry GJ, Burke MM, Demetris AJ, Hammond E, Itescu S, Marboe CC, McManus B, Reed EF, Reinsmoen NL, Rodriguez ER, Rose AG, Rose M, Suciu-Focia N, Zeevi A, Billingham ME. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. *J Heart Lung Transplant* [Internet]. 2005;24:1710–1720. Available from: http://dx.doi.org/10.1016/j.healun.2005.03.019
- Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Gutiérrez OM, Kalil R, Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby R, Rossing P, Rule AD, Selvin E, Seegmiller JC, Shlipak MG, Torres VE, Yang W, Ballew SH, Couture SJ, Powe NR, Levey AS. New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race. *N Engl J Med* [Internet]. 2021;385:1737–1749. Available from: https://doi.org/10.1056/NEJMoa2102953
- Bermpeis K, Esposito G, Gallinoro E, Paolisso P, Bertolone DT, Fabbricatore D, Mileva N, Munhoz D, Buckley J, Wyffels E, Sonck J, Collet C, Barbato E, De Bruyne B, Bartunek J, Vanderheyden M. Safety of Right and Left Ventricular Endomyocardial Biopsy in Heart Transplantation and Cardiomyopathy Patients. *JACC Heart Fail* [Internet]. 2022;10:963–973. Available from: http://dx.doi.org/10.1016/j.jchf.2022.08.005
- Rodgers N, Gerding B, Cusi V, Vaida F, Tada Y, Morris GP, Adler EA, Stehlik J, Kim PJ. Comparison of two donor-derived cell-free DNA tests and a blood gene-expression profile test in heart transplantation. *Clin Transplant* [Internet]. 2023;e14984. Available from: http://dx.doi.org/10.1111/ctr.14984
- Bates D, M\u00e4chler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. J Stat Softw [Internet]. 2015 [cited 2022 Jul 15];67:1–48. Available from: https://www.jstatsoft.org/article/view/v067i01/0
- 6. Canty A. Ripley B. boot: Bootstrap R (S-Plus) functions. R package version 1.3--23. 2019. 2021;
- 7. Wickham H. ggplot2: elegant graphics for data analysis Springer-Verlag New York; 2009. 2016;
- 8. Therneau, Grambsch. Modeling Survival Data: Extending the Cox Model 2000 New York. *NY Springer Crossref.*